Investors with the goal of beating the broader market often turn to stock selection. Strategic choices in individual stocks can have a profound impact on your wealth.
After finishing at $13.17 in the prior trading day, Trevi Therapeutics Inc (NASDAQ: TRVI) closed at $12.77, down -3.04%. In other words, the price has decreased by -$3.04 from its previous closing price. On the day, 1.84 million shares were traded. TRVI stock price reached its highest trading level at $13.45 during the session, while it also had its lowest trading level at $12.707.
Ratios:
Our goal is to gain a better understanding of TRVI by taking a closer look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 21.93 and its Current Ratio is at 21.93. In the meantime, Its Debt-to-Equity ratio is 0.00 whereas as Long-Term Debt/Eq ratio is at 0.00.
Upgrades & Downgrades
In the most recent recommendation for this company, Leerink Partners on November 13, 2025, initiated with a Outperform rating and assigned the stock a target price of $13.
On August 21, 2025, Morgan Stanley started tracking the stock assigning a Overweight rating and target price of $18.
On July 01, 2025, Cantor Fitzgerald started tracking the stock assigning a Overweight rating and target price of $25.Cantor Fitzgerald initiated its Overweight rating on July 01, 2025, with a $25 target price.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Oct 07 ’25 when Delfini Lisa bought 108,650 shares for $9.50 per share.
Delfini Lisa bought 40,000 shares of TRVI for $386,716 on Oct 03 ’25. On Aug 27 ’25, another insider, Delfini Lisa, who serves as the Officer of the company, bought 312,855 shares for $8.09 each.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, TRVI now has a Market Capitalization of 1637498880 and an Enterprise Value of 1443394816.
Stock Price History:
The Beta on a monthly basis for TRVI is 0.91, which has changed by 2.106132 over the last 52 weeks, in comparison to a change of 0.13613915 over the same period for the S&P500. Over the past 52 weeks, TRVI has reached a high of $14.39, while it has fallen to a 52-week low of $3.43. The 50-Day Moving Average of the stock is 12.20%, while the 200-Day Moving Average is calculated to be 61.31%.
Shares Statistics:
The stock has traded on average 2.00M shares per day over the past 3-months and 2656340 shares per day over the last 10 days, according to various share statistics. A total of 128.22M shares are outstanding, with a floating share count of 83.78M. Insiders hold about 34.67% of the company’s shares, while institutions hold 69.36% stake in the company. Shares short for TRVI as of 1764288000 were 13403743 with a Short Ratio of 6.69, compared to 1761868800 on 15623820. Therefore, it implies a Short% of Shares Outstanding of 13403743 and a Short% of Float of 12.020000999999999.
Earnings Estimates
The market rating of Trevi Therapeutics Inc (TRVI) is currently shaped by the ongoing analysis conducted by 7.0 analysts closely monitoring its performance.The consensus estimate for the next quarter is -$0.13, with high estimates of -$0.09 and low estimates of -$0.15.
Analysts are recommending an EPS of between -$0.35 and -$0.4 for the fiscal current year, implying an average EPS of -$0.37. EPS for the following year is -$0.46, with 8.0 analysts recommending between -$0.22 and -$0.66.
